Moreover, the JAK2 inhibitor BMS-911543 selectively targets CML-LSCs without affecting healthy progenitor/stem cells and its association with Dasatinib effectively eliminated primary TKI-insensitive CML-LSCs [48]. Here, JAK2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.